Search

Myopericarditis has been observed among individuals receiving the BNT162b2-mRNA and mRNA-1273 COVID-19 vaccines.1,2 In this case series, we describe the initial experience with myopericarditis following COVID-19 vaccination across the largest healthcare system in Connecticut.

Background: Despite the higher prevalence and excess morbidity associated with peripheral arterial disease (PAD) in blacks, as compared with whites, little is known about racial differences in clinical characteristics, treatment referral and health status outcomes (symptoms, functioning, quality of life) at the time of PAD presentation. Methods: We used data from the Patient-centered Outcomes Related to Treatment Practices in Peripheral Arterial Disease Investigating Trajectories (PORTRAIT) registry, a multicenter, international prospective study of patients with new or worsening PAD symptoms consulting specialty care (2011-2015). Clinical and treatment characteristics were abstracted from medical records and health status was collected via patient interviews at presentation using the Peripheral Artery Questionnaire (PAQ). We calculated summary statistics using t-test/chi-square analyses and examined mean differences in the PAQ summary score at baseline between blacks and whites. Results: The final cohort consisted of 760 patients (N=183 blacks; 24%). Compared with whites, blacks were younger (66±9.8 vs 70±9.2; P=< 0.001), more likely to be female (58% vs. 37%, P= Conclusion: Despite excess prevalence of adverse risk factors including diabetes, hypertension, and smoking, black patients presenting with PAD have similar health status outcomes and invasive treatment strategies when compared with whites. Follow-up studies are needed to determine if these observations persist after adjustment for covariates and if there are differences in health status recovery over time.

Transcatheter aortic valve replacement (TAVR) has evolved from the use of the Medtronic first generation CoreValve to the second generation Evolut R valve. Most studies have showed comparable if not improved performance of the Evolut R. However, individual trials are based on single center

We are reporting a case of Tako tsubo cardiomyopathy (transient left ventricular apical ballooning) in the Western population identified by a perfusion echocardiogram that demonstrated perfusion defect at baseline in the apical and adjacent walls that was incongruous to the wall-motion abnormality. The perfusion defect improved within 72 hours on a repeated study indicating that microvasculature disruption is a key feature of this enigmatic cardiomyopathy.